Literature DB >> 2008908

Inhibitors within the nephron.

F L Coe1, Y Nakagawa, J H Parks.   

Abstract

Kidney-derived inhibitors of crystal growth and aggregation prevent supersaturations created by water conservation from expressing themselves in pathological soft tissue calcifications and intranephronal crystallizations. These inhibitors include nephrocalcin (NC), an acidic glycoprotein produced in proximal tubules and thick ascending limbs of Henle's loop, and the Tamm-Horsfall glycoprotein (THP), produced only in the thick ascending limb. NC inhibits growth and aggregation of calcium oxalate monohydrate (COM), the major crystalline component of human renal stones, THP inhibits only COM aggregation. Patients who form COM stones produce abnormal NC molecules that lack gamma-carboxyglutamic acid and fail to inhibit COM crystallizations normally.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2008908     DOI: 10.1016/s0272-6386(12)80633-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  9 in total

Review 1.  Kidney stone disease today--an overview and some current developments.

Authors:  W C Thomas
Journal:  Trans Am Clin Climatol Assoc       Date:  1993

2.  Isoelectric focusing of Tamm-Horsfall glycoproteins: a simple tool for recognizing recurrent calcium oxalate renal stone formers.

Authors:  P Schnierle; F Hering; H Seiler
Journal:  Urol Res       Date:  1996

3.  Immunocytochemical localization of Tamm-Horsfall protein in the kidneys of normal and nephrolithic rats.

Authors:  J A Gokhale; M D McKee; S R Khan
Journal:  Urol Res       Date:  1996

Review 4.  Animal models of kidney stone formation: an analysis.

Authors:  S R Khan
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 5.  A hypothesis of calcium stone formation: an interpretation of stone research during the past decades.

Authors:  Hans-Göran Tiselius
Journal:  Urol Res       Date:  2011-01-19

6.  The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin.

Authors:  E M Worcester; J L Sebastian; J G Hiatt; A M Beshensky; J A Sadowski
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

Review 7.  Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate?

Authors:  Hans-Göran Tiselius
Journal:  Urolithiasis       Date:  2014-08-03       Impact factor: 3.436

Review 8.  Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development.

Authors:  S R Khan
Journal:  Urol Res       Date:  1995

9.  StoneMod: a database for kidney stone modulatory proteins with experimental evidence.

Authors:  Supatcha Sassanarakkit; Paleerath Peerapen; Visith Thongboonkerd
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.